World's Best Scientists 2026 revealed!
Richard N. Fedorak

Richard N. Fedorak

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 99 8463 7952 328 312 600 46083

Richard N. Fedorak publications per year

The chart shows the history of publications by Richard N. Fedorak between 1985 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Richard N. Fedorak published across 41 years, from 1985 to 2025, averaging 14.9 papers a year. Output peaked at 60 publications in 2018. 6 of the 609 publications appeared in the last two years.

No. of publications
20 40 60
Bar chart. Horizontal axis: year, 1985 to 2025. Vertical axis: number of publications, 0 to 60. Peak 60 publications in 2018. 1985: 2 publications 1986: 3 publications 1987: 2 publications 1988: 2 publications 1989: 7 publications 1990: 8 publications 1991: 6 publications 1992: 10 publications 1993: 9 publications 1994: 8 publications 1995: 12 publications 1996: 13 publications 1997: 9 publications 1998: 14 publications 1999: 11 publications 2000: 13 publications 2001: 9 publications 2002: 6 publications 2003: 13 publications 2004: 13 publications 2005: 15 publications 2006: 12 publications 2007: 14 publications 2008: 37 publications 2009: 33 publications 2010: 26 publications 2011: 30 publications 2012: 32 publications 2013: 27 publications 2014: 35 publications 2015: 34 publications 2016: 27 publications 2017: 28 publications 2018: 60 publications 2019: 15 publications 2020: 5 publications 2021: 3 publications 2022: 0 publications 2023: 0 publications 2024: 4 publications 2025: 2 publications
1985 2025

609 publications in total across all disciplines

View publications per year as a table
Richard N. Fedorak: publications per year, 1985 to 2025
Year Publications
1985 2
1986 3
1987 2
1988 2
1989 7
1990 8
1991 6
1992 10
1993 9
1994 8
1995 12
1996 13
1997 9
1998 14
1999 11
2000 13
2001 9
2002 6
2003 13
2004 13
2005 15
2006 12
2007 14
2008 37
2009 33
2010 26
2011 30
2012 32
2013 27
2014 35
2015 34
2016 27
2017 28
2018 60
2019 15
2020 5
2021 3
2022 0
2023 0
2024 4
2025 2
Total 609
Download as CSV

Richard N. Fedorak publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard N. Fedorak sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 581–600 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 600 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509 600
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Richard N. Fedorak D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard N. Fedorak sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 98–99 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668 99
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Research.com Recognitions

  • 2011 - Fellow of the Royal Society of Canada Academy of Science

Overview

Richard N. Fedorak is affiliated with the University of Alberta in Canada. Their research primarily centers on the field of medicine, with notable contributions in several specialized subfields including epidemiology, genetics, health information management, surgery, and artificial intelligence.

The scientist's main topics of work span a range of areas related to gastrointestinal and healthcare technologies. These topics include:

  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Eosinophilic Esophagitis
  • Electronic Health Records Systems
  • Artificial Intelligence in Healthcare
  • Machine Learning in Healthcare
  • Biosimilars and Bioanalytical Methods

Frequent co-authors collaborating with Richard N. Fedorak comprise:

  • Reed T. Sutton
  • Karen I. Kroeker
  • Ellina Lytvyak
  • Levinus A. Dieleman
  • Farhad Peerani

Publication venues frequently featuring their work include:

  • Journal of the Canadian Association of Gastroenterology
  • npj Digital Medicine
  • Inflammatory Bowel Diseases
  • Digestive Diseases and Sciences
  • Crohn s & Colitis 360

Recent papers authored or co-authored by Richard N. Fedorak cover topics from clinical decision support systems to trends in surgical incidence and management of inflammatory bowel diseases. Notable recent publications include:

  • "An overview of clinical decision support systems: benefits, risks, and strategies for success" (2020), published in npj Digital Medicine
  • "Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis" (2020), published in Inflammatory Bowel Diseases
  • "Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease" (2020), published in Digestive Diseases and Sciences
  • "Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization" (2020), published in Crohn s & Colitis 360
  • "A162 OBESITY IS A RISK FACTOR FOR THE DEVELOPMENT OF THE EXTRAINTESTINAL MANIFESTATIONS IN ULCERATIVE COLITIS, BUT NOT IN CROHN'S DISEASE" (2021), published in Journal of the Canadian Association of Gastroenterology

Richard N. Fedorak was awarded the designation of Fellow of the Royal Society of Canada in 2011 within the Academy of Science.

Best Publications

  • Infliximab Maintenance Therapy for Fistulizing Crohn's Disease

    Bruce E. Sands;Frank H. Anderson;Charles N. Bernstein;William Y. Chey

  • Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

    William J. Sandborn;Brian G. Feagan;Paul Rutgeerts;Stephen Hanauer

  • Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

    Stephen B. Hanauer;William J. Sandborn;Paul Rutgeerts;Richard N. Fedorak

  • An overview of clinical decision support systems: benefits, risks, and strategies for success.

    Reed T. Sutton;David Pincock;Daniel C. Baumgart;Daniel C. Sadowski

  • Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial

    William J Sandborn;Stephen B Hanauer;Paul J Rutgeerts;Richard N Fedorak

  • Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.

    Brian G Feagan;Gordon R Greenberg;Gary Wild;Richard N Fedorak

  • Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice.

    Karen L. Madsen;Jason S. Doyle;Laurence D. Jewell;Michele M. Tavernini

  • Methotrexate for the Treatment of Crohn's Disease

    B G Feagan;J Rochon;R N Fedorak;E J Irvine

  • VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

    Rodrigo Bibiloni;Richard N Fedorak;Gerald W Tannock;Karen L Madsen

  • A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.

    B G Feagan;R N Fedorak;E J Irvine;G Wild

  • The epidemiology of inflammatory bowel disease in Canada: a population-based study.

    Charles N Bernstein;Andre Wajda;Lawrence W Svenson;Adrian MacKenzie

  • Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

    Walter Reinisch;William J Sandborn;Daniel W Hommes;Geert D'Haens

  • A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

    Stefan Schreiber;Paul Rutgeerts;Richard N. Fedorak;Munaa Khaliq–Kareemi

  • Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

    Stephan R. Targan;Brian G. Feagan;Richard N. Fedorak;Bret A. Lashner

  • A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.

    William J. Sandborn;Brian G. Feagan;Richard N. Fedorak;Ellen Scherl

  • Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease

    Richard N. Fedorak;Alfred Gangl;Charles O. Elson;Paul Rutgeerts

  • Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease

    E. J. Irvine;B. Feagan;J. Rochon;A. Archambault

  • Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.

    S.J.H. van Deventer;C.O. Elson;R.N. Fedorak

  • The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting.

    Alan Barkun;Sandrine Sabbah;Robert Enns;David Armstrong

  • World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011.

    Francisco Guarner;Aamir G. Khan;James Garisch;Rami Eliakim

Frequent Co-Authors

Brian G. Feagan
Brian G. Feagan University of Western Ontario
Remo Panaccione
Remo Panaccione University of Calgary
William J. Sandborn
William J. Sandborn University of California, San Diego
Stefan Schreiber
Stefan Schreiber Kiel University
Gilaad G. Kaplan
Gilaad G. Kaplan University of Calgary
Subrata Ghosh
Subrata Ghosh University College Cork
Stephen B. Hanauer
Stephen B. Hanauer Northwestern University
Jean-Frederic Colombel
Jean-Frederic Colombel Icahn School of Medicine at Mount Sinai

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the US doesn’t always follow a single path. For those seeking different entry points or advancement opportunities in healthcare, there are several flexible online degree options tailored to various needs.

Registered Nurses can take advantage of online rn to bsn programs without clinical requirements. These programs allow working professionals to further their education on their own schedule and without the need for in-person practice hours.

Aspiring leaders and practitioners interested in a Doctor of Nursing Practice (DNP) can consider dnp online programs for a flexible format. Additionally, students looking to accelerate their study can choose from the dnp program without clinical hours—ideal for those wanting a streamlined approach to advanced roles.

Entry-level positions are also accessible, thanks to options like the lpn program. Fast-track online LPN programs make it possible to start your career in patient care quickly and affordably.

Best Scientists Citing Richard N. Fedorak

Trending Scientists

Recently Published Articles